Literature DB >> 31291891

The difference in serum proteomes in schizophrenia and bipolar disorder.

Liudmila Smirnova1, Alexander Seregin2, Irina Boksha3, Elena Dmitrieva2,4, German Simutkin2, Elena Kornetova2,4, Olga Savushkina3, Anastasia Letova4, Nikolay Bokhan2, Svetlana Ivanova2,4, Victor Zgoda5.   

Abstract

BACKGROUND: Purpose of study is revealing significant differences in serum proteomes in schizophrenia and bipolar disorder (BD).
RESULTS: Quantitative mass-spectrometry based proteomic analysis was used to quantify proteins in the blood serum samples after the depletion of six major blood proteins. Comparison of proteome profiles of different groups revealed 27 proteins being specific for schizophrenia, and 18 - for BD. Protein set in schizophrenia was mostly associated with immune response, cell communication, cell growth and maintenance, protein metabolism and regulation of nucleic acid metabolism. Protein set in BD was mostly associated with immune response, regulating transport processes across cell membrane and cell communication, development of neurons and oligodendrocytes and cell growth. Concentrations of ankyrin repeat domain-containing protein 12 (ANKRD12) and cadherin 5 in serum samples were determined by ELISA. Significant difference between three groups was revealed in ANKRD12 concentration (p = 0.02), with maximum elevation of ANKRD12 concentration (median level) in schizophrenia followed by BD. Cadherin 5 concentration differed significantly (p = 0.035) between schizophrenic patients with prevailing positive symptoms (4.78 [2.71, 7.12] ng/ml) and those with prevailing negative symptoms (1.86 [0.001, 4.11] ng/ml).
CONCLUSIONS: Our results are presumably useful for discovering the new pathways involved in endogenous psychotic disorders.

Entities:  

Keywords:  Biomarker; Bipolar disorder; Mass spectrometry; Proteome; Schizophrenia; Serum

Mesh:

Substances:

Year:  2019        PMID: 31291891      PMCID: PMC6620192          DOI: 10.1186/s12864-019-5848-1

Source DB:  PubMed          Journal:  BMC Genomics        ISSN: 1471-2164            Impact factor:   3.969


  10 in total

Review 1.  The Role of Brain Microvascular Endothelial Cell and Blood-Brain Barrier Dysfunction in Schizophrenia.

Authors:  Sovannarath Pong; Rakesh Karmacharya; Marianna Sofman; Jeffrey R Bishop; Paulo Lizano
Journal:  Complex Psychiatry       Date:  2020-09-14

Review 2.  Systematic Review and Meta-Analysis of Mass Spectrometry Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Schizophrenia.

Authors:  João E Rodrigues; Ana Martinho; Catia Santa; Nuno Madeira; Manuel Coroa; Vítor Santos; Maria J Martins; Carlos N Pato; Antonio Macedo; Bruno Manadas
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

Review 3.  Systematic Review and Meta-Analysis on MS-Based Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Bipolar Disorder.

Authors:  Joao E Rodrigues; Ana Martinho; Vítor Santos; Catia Santa; Nuno Madeira; Maria J Martins; Carlos N Pato; Antonio Macedo; Bruno Manadas
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 4.  Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives.

Authors:  Evgeny A Ermakov; Elena M Dmitrieva; Daria A Parshukova; Daria V Kazantseva; Alisa R Vasilieva; Liudmila P Smirnova
Journal:  Oxid Med Cell Longev       Date:  2021-01-23       Impact factor: 6.543

5.  Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study.

Authors:  Irina A Mednova; Alexander A Chernonosov; Marat F Kasakin; Elena G Kornetova; Arkadiy V Semke; Nikolay A Bokhan; Vladimir V Koval; Svetlana A Ivanova
Journal:  Metabolites       Date:  2021-01-05

6.  A serum proteomic study of two case-control cohorts identifies novel biomarkers for bipolar disorder.

Authors:  Andreas Göteson; Anniella Isgren; Timea Sparding; Jessica Holmén-Larsson; Joel Jakobsson; Erik Pålsson; Mikael Landén
Journal:  Transl Psychiatry       Date:  2022-02-08       Impact factor: 7.989

7.  Proteomic Analysis of Plasma Markers in Patients Maintained on Antipsychotics: Comparison to Patients Off Antipsychotics and Normal Controls.

Authors:  Rudolf Engelke; Sami Ouanes; Suhaila Ghuloum; Rifka Chamali; Nancy Kiwan; Hina Sarwath; Frank Schmidt; Karsten Suhre; Hassen Al-Amin
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 4.157

8.  Proteomic profile of serum from patients with schizophrenia spectrum disorders.

Authors:  Elena Dmitrieva; Liudmila Smirnova; Alexander Seregin; Victor Zgoda; Arkadij Semke; Svetlana Ivanova
Journal:  PeerJ       Date:  2022-08-30       Impact factor: 3.061

9.  Cerebrospinal fluid proteomics targeted for central nervous system processes in bipolar disorder.

Authors:  Andreas Göteson; Anniella Isgren; Lina Jonsson; Timea Sparding; Erik Smedler; Aurimantas Pelanis; Henrik Zetterberg; Joel Jakobsson; Erik Pålsson; Jessica Holmén-Larsson; Mikael Landén
Journal:  Mol Psychiatry       Date:  2021-08-04       Impact factor: 15.992

10.  Extracellular LGALS3BP regulates neural progenitor position and relates to human cortical complexity.

Authors:  Christina Kyrousi; Adam C O'Neill; Agnieska Brazovskaja; Zhisong He; Pavel Kielkowski; Laure Coquand; Rossella Di Giaimo; Pierpaolo D' Andrea; Alexander Belka; Andrea Forero Echeverry; Davide Mei; Matteo Lenge; Cristiana Cruceanu; Isabel Y Buchsbaum; Shahryar Khattak; Guimiot Fabien; Elisabeth Binder; Frances Elmslie; Renzo Guerrini; Alexandre D Baffet; Stephan A Sieber; Barbara Treutlein; Stephen P Robertson; Silvia Cappello
Journal:  Nat Commun       Date:  2021-11-02       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.